Sauter, M.; Haag, J.; Bay, C.; Leuschner, F.; Haefeli, W.E.; Kuhn, T.C.; Burhenne, J.
Bioanalysis of the Ex Vivo Labile PACE4 Inhibitory Peptide Ac-[d-Leu]LLLRVK-Amba in Whole Blood Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Quantification. Pharmaceutics 2023, 15, 2745.
https://doi.org/10.3390/pharmaceutics15122745
AMA Style
Sauter M, Haag J, Bay C, Leuschner F, Haefeli WE, Kuhn TC, Burhenne J.
Bioanalysis of the Ex Vivo Labile PACE4 Inhibitory Peptide Ac-[d-Leu]LLLRVK-Amba in Whole Blood Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Quantification. Pharmaceutics. 2023; 15(12):2745.
https://doi.org/10.3390/pharmaceutics15122745
Chicago/Turabian Style
Sauter, Max, Jonas Haag, Cindy Bay, Florian Leuschner, Walter E. Haefeli, Tim Christian Kuhn, and Jürgen Burhenne.
2023. "Bioanalysis of the Ex Vivo Labile PACE4 Inhibitory Peptide Ac-[d-Leu]LLLRVK-Amba in Whole Blood Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Quantification" Pharmaceutics 15, no. 12: 2745.
https://doi.org/10.3390/pharmaceutics15122745
APA Style
Sauter, M., Haag, J., Bay, C., Leuschner, F., Haefeli, W. E., Kuhn, T. C., & Burhenne, J.
(2023). Bioanalysis of the Ex Vivo Labile PACE4 Inhibitory Peptide Ac-[d-Leu]LLLRVK-Amba in Whole Blood Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Quantification. Pharmaceutics, 15(12), 2745.
https://doi.org/10.3390/pharmaceutics15122745
